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Abstract
Alzheimer’s disease (AD) causes devastating cognitive impairment and an intense
research effort is currently devoted to developing improved treatments for it. A
minority of cases occur at a particularly young age and are caused by autosomal
dominantly inherited genetic mutations. Although rare, familial AD provides unique
opportunities to gain insights into the cascade of pathological events and how they
relate to clinical manifestations. The phenotype of familial AD is highly variable and,
although it shares many clinical features with sporadic AD, it also possesses
important differences. Exploring the genetic and pathological basis of this phenotypic
heterogeneity can illuminate aspects of the underlying disease mechanism, and is
likely to inform our understanding and treatment of AD in the future.
Keywords: Familial Alzheimer’s disease, Presenilins, Amyloid precursor protein,
early onset dementia, Dominantly inherited Alzheimer’s diseaseIntroduction
Observations that cases of early onset Alzheimer’s disease (EOAD) may cluster
within families were made as early as the 1930s, and almost two decades have now
passed since the first reports confirming that the disease could be caused by
autosomal dominantly inherited genetic mutations. Initially identified in the amyloid
precursor protein (APP) gene on chromosome 21,
(1) mutations were also subsequently
found in the genes encoding presenilin one (PSEN1) on chromosome 14
(2) and
presenilin two (PSEN2) on chromosome 1.
(3) Over two hundred changes have now
been described in these genes, although some are thought to represent non-pathogenic
polymorphisms and in other cases, the pathogenic nature of the change is as yet
unclear. More recently, duplications of the APP gene have been identified as an
additional cause of familial Alzheimer’s disease (FAD).
(4) Mutations in PSEN1
account for the majority of cases of FAD and it is in PSEN1 that the greatest numbers
of mutations have been found, with 177 recorded to date compared to 32 and 14 in
APP and PSEN2 respectively.
(102)(See Figures 1,2 and 3) Collectively, these
mutations are thought to account for up to 0.5% of Alzheimer’s disease in general.
(102)
The degree to which familial Alzheimer’s disease may be a paradigm for the
commoner, late onset, sporadic form of the disease is uncertain but the insights
gleaned from the study of FAD have catalysed much of our current knowledge of the
pathobiological basis of the disease. The development of cellular models and
transgenic mice harbouring mutations in APP and the presenilins has allowed the
disease mechanism to be explored in detail and probed with potential therapeutic
agents. As these therapies come closer to clinical application, the debate regarding
how generalisable the changes of FAD are to those of sporadic AD grows in
significance. Unravelling the pathway through which specific genetic mutations
translate into the manifestations of clinical Alzheimer’s disease, and how the resulting
phenotypes may vary, are clearly important areas of investigation. Although much has
been published describing novel FAD gene mutations and exploring their functional
effects at a molecular level, there have been far fewer detailed reports of the resulting
clinical phenotypes.
(5) (6) In this review, we examine how closely the phenotype of
FAD resembles and differs from that of sporadic AD. We emphasise the importance
of appreciating the degree of phenotypic heterogeneity within FAD. Finally, wediscuss several mechanisms by which the clinical picture, and underlying pathology,
may be influenced by genotype.
The role of genetic mutations in AD pathogenesis
The pathological hallmarks of Alzheimer’s disease in both familial and sporadic cases
are extracellular plaques of amyloid-β (Aβ) and intraneuronal inclusions of
hyperphosphorylated tau. It is now well recognised that mutations in all three genes
known to cause FAD ultimately result in enhanced production and/or deposition of
Aβ.
(7) The mechanisms through which they achieve this are complex and variable.
APP is a transmembrane protein whose function is not yet fully determined, although
it appears to play a role in neural plasticity and the regulation of synapse formation.
APP may be proteolytically cleaved by α, β and γ secretases and, during its normal
metabolism, it can undergo cleavage via alternative pathways. Cleavage by α-
secretase is considered to be part of the non-amyloidogenic pathway in APP
processing. It precludes Aβ formation as it cleaves within the segment of APP that
would otherwise give rise to Aβ. Upon cleavage by α-secretase, APP releases its
extracellular domain, a fragment called APPsα, which is known to have neurotrophic
effects. Alternatively, APP may undergo sequential cleavage by β and γ secretase. 
Extracellular cleavage by β-secretase (also known as BACE1: β-site of APP cleaving
enzyme) generates a soluble extracellular fragment and is followed by cleavage of
APP within its transmembrane domain by γ secretase. The unusual property of γ-
secretase is that it may cleave APP at a variety of different sites, generating a peptide
from 39-43 amino acids in length; the amyloid- β (Aβ) protein. PSEN1 forms part of
the γ secretase complex and the majority of pathogenic PSEN1 mutations are located
in areas thought to lie in the vicinity of its transmembrane domains. Under normal
conditions, the majority of Aβ takes the form of the 40 amino acid long peptide Aβ40.
There is some additional production of the longer moiety; Aβ42, which accounts for
5-15% of the total pool of Aβ in health. Smaller quantities of other Aβs, both longer
and shorter, may also be observed. Aβ peptides, particularly Aβ-42, can cause toxic
effects on neuronal and synaptic function as intracellular oligomers and seed to form
extracellular precipitates in the form of amyloid plaques. Aβ-42 is the most
amyloidogenic form of the peptide; its hydrophobic nature makes it more susceptibleto conformational change leading to amyloid fibrillogenesis. Most FAD-causing
mutations appear to either increase Aβ-40 and Aβ-42 or alter the ratio between them.
However, the discovery of the ‘Arctic’ APP mutation (E693G) in a Swedish family,
which is located away from the secretase sites, led to the suggestion of an alternative
pathogenic mechanism. Aβ-40 and Aβ-42 are actually found in decreased levels with
this mutation, however they have an increased propensity to form protofibrils, which
may accelerate their deposition in intracellular or extracellular locations, or both.
(8)
Figure 1. APP gene with mutations indicated
Diagram courtesy of Richard Crook, Mayo Clinic Jacksonville, and John Hardy,
Institute of Neurology, University College London.Figure 2. Presenilin 1 gene with mutations indicated
Reprinted from International Review of Cytology, Vol 254, Dillen K. & Annaert W.,
A two decade contribution of molecular cell biology to the centennial of Alzheimer’s
disease: are we progressing towards therapy?, Pages 215-300, Copyright (2006), with
permission from Elsevier.
FAD-linked mutations are indicated in red, while non-pathogenic mutations are
marked in orange. Interaction domains with APP/TLN or NCT/APH-1/PEN-2 are
marked in blue, as well as the conserved residues D257 and D385 forming the
putative catalytic site. Interactions of the C-terminal domain and the hydrophilic loop
domain with proteins such as the brain G-protein Go, calsenilin, the PSEN1-
associated protein (PSAP), b- and d-catenin, p0071 and PLD1, are shown in dark
green. The endoproteolytic cleavage site separating PSEN1-NTF and -CTF in the
seventh hydrophobic region, the SPP cleavage site in the ninth TMD and the caspase
cleavage site in the hydrophilic loop domain are indicated by yellow arrows.Figure 3. Presenilin 2 gene with mutations indicated
Diagram courtesy of Richard Crook, Mayo Clinic Jacksonville, and John Hardy,
Institute of Neurology, University College London.
Clinical manifestation of disease
The most striking difference between familial and sporadic AD is the younger age at
onset in individuals harbouring FAD mutations. That the disease should manifest at
an earlier age is not surprising, given the increased β-amyloid deposition that these
mutations cause. The youngest ages at onset are seen in families with PSEN1
mutations, which typically fall within the range 35-55 years. APP mutations tend to
give rise to symptom onset between 40-65 years and PSEN2 mutations between 40-70
years. It has been suggested that, as well as being associated with a younger age atonset of disease, PSEN1 mutations give rise to shorter disease durations (4.8-6.8
years) than PSEN2 and APP mutations (range 4.4 – 10.8 years and 9.0 – 16 years
respectively).
(9) However, the survival data of different series demonstrate
considerable variation. Although the disease course of FAD is often considered to be
more aggressive, some reports find comparable disease durations for the familial and
sporadic forms of AD.
(10) Drawing direct comparisons between disease duration in
familial and sporadic AD is problematic as survival is likely to be affected by age at
onset itself. Younger, healthier patients may survive longer at more severe stages of
disease than older patients with sporadic AD, who are generally more frail and often
have additional co-morbidities. Another major difficulty in interpreting survival data
is that estimates for age at symptom onset are highly subjective and unreliable.
Symptoms tend to develop insidiously so, in some cases, may pass unrecognised for
quite some time. On the other hand, as awareness of the heritable nature of the disease
heightens with subsequent generations, symptoms are likely to be noticed at an earlier
stage. This probably contributes to the range in age at onset that is witnessed both
between and within families with the same mutation. However, other genetic and
epigenetic factors are also likely to be important in modulating age at onset.
Other genetic modifiers
Pathological studies have shown that the proportion of brain tissue occupied by Aβ-
42-containing plaques is significantly higher in PS1-associated AD than sporadic AD.
Although there does not appear to be a difference in the amount of tissue containing
Aβ-40 between these two disease groups, both PS1-AD and sporadic AD show the
same relationship between Aβ deposition and APOE genotype: Individuals who carry
an E4 allele demonstrate a greater proportion of Aβ-40 deposition in both familial and
sporadic disease. It has been suggested that, in the presence of the apolipoprotein E4
isoform, the threshold for Aβ-40 fibrillisation is decreased, fostering the deposition of
Aβ-40 onto Aβ-42-containing plaques.
(11) It has also been shown that possession of
the APOE4 allele in FAD secondary to APP mutations is associated with a decreased
age at onset, as is the case in sporadic AD. In PSEN1 mutations, this modifying effect
on age at onset by the E4 allele was not previously thought to occur.
(12) However,
when a single large Colombian kindred with the E280A PSEN1 mutation was
examined, possession of the APOE4 allele did appear to be associated with an earlierage at onset.
(13) The true nature of the relationship between APOE status and FAD
mutations will probably only be elucidated when much larger cohorts are studied.
Cognitive phenotypes
Amnestic presentations
The majority of individuals with FAD have similar clinical presentations to those with
sporadic AD, comprising early impairment of episodic memory which gradually
progresses to involve multiple cognitive domains. Longitudinal studies of individuals
at risk of FAD demonstrate that the earliest neuropsychological manifestations are a
fall in verbal memory and performance IQ scores, occurring even 2-3yrs
presymptomatically.
(14) The neuropsychological profile of FAD at a group level has
also been found to show relatively well preserved naming, spelling and
visuoperceptual skills compared with sporadic AD in the early stages.
(15) (10) There
can therefore be a particularly long prodromal phase in FAD, where subtle memory
problems are the only clinical feature for several years.
(10) Presymptomatic cognitive
deficits are accompanied by neuroimaging changes, with accelerating rates of whole
brain and hippocampal atrophy in the five years prior to symptom onset.
(16) (17)
The early stages of sporadic AD have been harder to study. Historically, individuals
with memory concerns have tended to seek medical attention only when their
symptoms are well established. However, we are currently witnessing a change in the
tide of public opinion towards an appreciation of the importance of early diagnosis.
There is increased recognition that most patients with sporadic AD are likely to have
experienced a period of relatively isolated, usually amnestic, deficits termed mild
cognitive impairment (MCI) prior their diagnosis of AD.
(18) The term MCI is usually
used to refer to individuals with cognitive decline which is more than anticipated from
normal aging but insufficient to fulfil criteria for dementia. The term will thus be
applied to a heterogeneous group, not all of whom will develop AD, and there is
currently a great research effort aimed at better characterising these individuals and
refining the definition of the MCI label. Nevertheless, there are now many lines ofevidence supporting the notion that sporadic AD is preceded by a long prodromal
stage. The canonical FAD phenotype, manifesting with early progressive impairment
of episodic memory, can perhaps then be viewed as equivalent to the typical amnestic
AD phenotype, preceded by MCI, which is seen commonly in sporadic disease.
Many atypical presentations of FAD have, however, been reported and there can be
significant heterogeneity both between and within families regarding clinical
phenotype. Heterogeneity, however, also exists within sporadic AD and as
recognition of these more unusual variants increases, they may be found to occur
more frequently than was previously appreciated.
Language presentations
Several PSEN1 mutations have been reported to present with language impairment
including G209V, H163Y and R278I, which was detected in one patient given an
initial clinical diagnosis of progressive non-fluent aphasia.
(19) Language deficits have
been described in association with many other mutations later in the disease course, as
is also often the case in sporadic AD. There is a growing body of research aiming to
better characterise individuals with neurodegenerative disease who have predominant
impairments of language function at presentation. Primary progressive aphasia (PPA)
is traditionally thought to signify a disease in the spectrum of frontotemporal lobar
degenerations. However, a ‘logopenic’ variant (LPA) of PPA has recently been
proposed, in which AD appears to be the commonest underlying pathology.
(20)
Behavioural and psychiatric presentations
In sporadic AD, symptoms of agitation, depression, delusions and hallucinations
occur commonly, particularly in the later stages of disease. Many PSEN1 mutations
are associated with behavioural and psychiatric symptoms during the course of the
disease and these can, rarely, be the presenting features. Prominent early behavioural
symptoms have also been reported in association with several PSEN2 mutations,
including M239V, T122R and Y231C.
(21) An underlying pathological diagnosis of
AD has been obtained for some PSEN1 mutations where a behavioural presentation
has been described, including V89L
(22), L226F
(23) and M139V
(24). It has been
suggested that a distribution of pathology involving structures in frontal-subcorticalcircuits, such as the thalamus and striatum, may contribute to the behavioural
phenotype in some of these patients.
(22) Pathological confirmation for other PSEN1
mutations such as L113P remains to be established.
(25) In some cases, the presence of
behavioural and language features has been prominent enough to prompt a clinical
diagnosis of frontotemporal dementia (FTD), as was the case for the PSEN1 insR352
genotype.
(26) (27) It was initially hypothesised that this PSEN1 genotype may be
capable of inducing a distinct neurodegenerative illness, more akin to FTD than AD.
Intriguingly, not only did the members of the kindred have an FTD phenotype but
when an affected individual eventually came to autopsy, ubiquitin pathology typical
of FTD was found. The subsequent discovery of the progranulin gene as a cause of
familial FTD led to a re-evaluation of this case, which was indeed found to harbour a
progranulin mutation.
(28) With the benefit of hindsight, the change in PSEN1 was then
reconsidered to be a non-pathogenic polymorphism. This case highlights the
importance of exercising caution when ascribing pathogenicity to rare PSEN1
variants, especially when the phenotype is unusual.
Visual presentations
Visuospatial and visuoperceptual deficits commonly occur in the later stages of both
sporadic and familial AD. In sporadic AD, a posterior cortical atrophy variant may
occur, where marked visual processing deficits are the presenting features and
memory is relatively well preserved until later in the disease.
(29) This phenotype has
not, to date, been observed in FAD.
Neurological symptoms and signs
Neurological symptoms and signs tend to be more prominent in FAD than sporadic
AD, and have been recognised as a feature of the disease ever since it was first
reported. Myoclonus and seizures are common. Spastic paraparesis, extrapyramidal
signs and cerebellar ataxia have also been described, though less frequently. All of
these features are particularly prominent in kindreds with very early onset of
symptoms, below the age of 40.
(30) However, it is important to note that significant
phenotypic heterogeneity is observed, both between families sharing a commonmutation and within the affected individuals of a single family. Whilst all of these
unusual features do appear to occur more frequently in familial than sporadic AD, the
fact that younger patients often survive to more severe stages of disease may
contribute in part to the trend. Furthermore, the preference for reporting atypical cases
of FAD over those with sporadic AD may also play a role. In some reports,
particularly those including longitudinal assessments, it is clear that neurological
symptoms and signs developed at an early stage of the disease and there are cases
where these features predate cognitive impairment (Table 1). However, other reports
of ‘early’ atypical features should be read with caution as sometimes the disease may
be well established by the time a patient first presents to a clinician.
Myloclonus and seizures
Myloclonus can be a particularly prominent and early sign in FAD, in contrast to
sporadic AD where it tends to become apparent later in the course of the disease. The
same pattern appears to occur with seizures, which can occur more frequently and at
an earlier stage in the disease in FAD than in sporadic AD.
(31) Myoclonus and
seizures are observed more often in very early onset cases of FAD. In fact, in one
family with the PSEN1 L166P mutation and a young age at onset between 29-35
years, tonic-clonic seizures pre-dated the onset of cognitive impairment.
(32) Fine
finger myoclonus has also been noted to occur prior the onset of objective memory
impairment, although it may not necessarily be apparent to the patient or their family
at this mild early stage.
(10) Interestingly, there is a cluster of mutations associated with
early myoclonus and seizures in the region encoding transmembrane domain III of the
PSEN1 gene (S169L, S169P, S170F). Early myoclonus and seizures are also observed
in individuals with APP mutations and particularly with APP duplications, see below.
Spastic paraparesis
Spastic paraparesis has been reported in association with over twenty different PSEN1
mutations.
(33) Symptoms of spastic paraparesis may occur simultaneously with
cognitive deficits or may predate them by several years. Progressive spastic
paraparesis occurring for over a decade prior to the onset of cognitive impairment has
been reported in association with the PSEN1 R278K mutation.
(34) There is a particular
association of spastic paraparesis with PSEN1 exon 9 deletions, although not allindividuals with these deletions demonstrate the phenotype.
(35) In those who do, there
are frequently characteristic histological findings of large, rounded plaques in the
frontal cortex known as ‘cotton wool plaques’.
(36) Composed of Aβ40 and 42, cotton
wool plaques usually lack a compact amyloid core and show very little neuritic
change or glial cell component. The spastic paraparesis phenotype of FAD is often not
associated with any specific imaging findings. However, significant white matter
abnormalities on cranial MRI, presumed secondary to amyloid angiopathy, have been
observed in a family exhibiting spastic paraparesis and cotton wool plaques secondary
to the E280G PSEN1 mutation.
(37)
Several hypotheses have been proposed to explain why certain PSEN1 mutations may
give rise to the spastic paraparesis phenotype. The observation that most of the
mutations associated with spastic paraparesis cause exceptionally high levels of Aβ42
suggests that a dosage effect may be operating.
(38) Intraneuronal Aβ may also play a
role; this is a more frequent finding in AD patients with cotton wool plaques. As
intraneuronal Aβ is known to induce only a weak immune response, it has been
postulated that cotton wool plaques may result from a combination of increased Aβ
production and decreased clearance.
(39) However, the presence of cotton wool
plaques per se is not enough to explain the phenotype as these have also been found in
patients lacking signs of spastic paraparesis.
(40) Furthermore, the presence of spastic
paraparesis is highly variable, even between the affected individuals of a single family
sharing identical mutations and similar environmental exposures. There may,
therefore, be additional as yet unidentified factors operating in these patients that
drive the pathology towards structures, like the corticospinal tracts and motor cortex,
which are usually spared in both familial and sporadic AD.
Extrapyramidal signs
Extrapyramidal signs have been reported in association with several different PSEN1
mutations, particularly those causing very early onset disease and other neurological
signs such as spastic paraparesis.
(41) A novel PSEN2 mutation (A85V) has also
recently been reported where Parkinsonism was a feature .
(42) In the majority of cases,
the Parkinsonism does not become apparent until several years into the clinical
course. However, an extrapyramidal syndrome characterised by rigidity, bradykinesiaand an abnormal posture and gait was present from the onset of cognitive symptoms
in the first reported kindred harbouring the PSEN1 G217D mutation.
(43) The autopsy
findings in this family included, in addition to neurofibrillary tangles, amyloid
angiopathy and neuritic plaques, neuronal rarefaction in the substantia nigra and
numerous cotton wool plaques. These were distributed throughout the cerebral cortex
but were also concentrated in subcortical structures, particularly the striatum. As the
authors suggest, the topography of pathology in these patients could account for their
clinical presentations. Furthermore these cases illustrate how the separate, yet often
overlapping, phenotypes of spastic paraparesis and Parkinsonism in FAD may share a
common pathological substrate of cotton wool plaques located in specific anatomical
areas.
Another histological feature that can underlie a Parkinsonian presentation of FAD is
Lewy body pathology (LBP). Both LBP and cotton wool plaques were detected in a
patient exhibiting a dopa-responsive Parkinsonian syndrome who developed cognitive
symptoms seven years after the onset of his movement disorder. He was found to
possess a novel three base pair deletion (DelT440) in PSEN1.
(44) Widespread
neocortical LBP has been demonstrated in a kindred with very early onset FAD
secondary to an S170F PSEN1 mutation, in which the age at symptom onset was as
young as 26.
(30) In this family, myoclonus, seizures and extrapyramidal signs were
features of the disease. Parkinsonism, seizures, a very early onset of disease and LBP
were also reported in association with the M233V mutation in PSEN1.
(45) However,
not all FAD patients with extrapyramidal signs are found to have LBP and equally,
many patients with LBP do not manifest Parkinsonism clinically. In fact, concomitant
LBP is a frequent finding in neuropathological examinations of patients with both
familial and sporadic AD, occurring in up to 60% patients with each disease
according to some series.
(46) (47) Studies including analysis of the frequency of LBP in
different FAD gene mutations have suggested that PSEN1 mutations are significantly
more likely to have associated LBP than PSEN2 mutations.
(48) Furthermore, there
appear to be mutation-specific effects on the development of LBP in FAD. Certain
PSEN1 mutations such as A260V are associated with diffuse LBP whereas in others,
like G209V, the LBP seems to occur in the amygdala only. In other PSEN1
mutations, such as A246E, there tends to be very little LBP at all.
(46) LBP has also
been observed in association with APP mutations and, with both the Presenilins andAPP, no correlations between mutation position and the development of this
pathological picture have been identified.
(45) It has been suggested that the presence of
diffuse LBP in FAD is associated with longer durations of disease than when the LBP
is restricted to limbic areas.
(48) However, a detailed understanding of the significance
of LBP in FAD and how LBP relates to duration and manifestation of disease remains
to be elucidated, particularly as many studies were conducted before synuclein
antibodies became available.
Cerebellar signs
Variable cerebellar Aβ deposition has been observed in both familial and sporadic
AD.
(49) (50) In several PS1 mutations, particularly E280A,
(51) I143T,
(52) M139V
(53) and
G209V
(54) severe involvement of the cerebellum by Aβ plaque deposition has been
noted. This has also been found in FAD secondary to the APP717 mutations
(55) and in
the brains of elderly patients with Down’s syndrome.
(56,57) Even in cases of FAD with
similar amounts of Aβ deposition to sporadic AD in the cerebellum, cerebellar
Purkinje cell loss and reactive astrocytosis are significantly more severe in FAD than
sporadic AD.
(58) Pathological involvement of the cerebellum may occur without
cerebellar signs featuring in the clinical presentation.
(5) However, progressive
cerebellar ataxia has been reported as preceding cognitive impairment in the S170F
(59) and P117A
(60) mutations in PSEN1. Furthermore, cerebellar signs have been
observed during the disease course in a range of other mutations in PSEN1, including
L282V.
(61) This mutation is notable for its association with an unusually high amount
of amyloid angiopathy, which was found to involve the cerebellum in the individual
manifesting cerebellar signs.Table 1. Neurological presentations of familial Alzheimer’s disease
Neurological symptoms and signs occur commonly in FAD and may, more rarely,
represent the initial clinical features, as summarised below.
Clinical Feature Mutation Unusual pathology
Seizures and
myoclonus
PSEN1 N135S
PSEN1 L166P
PSEN1 L235P
‘London’APP V717I
‘Iranian’ APP T714A
APP duplication Amyloid angiopathy & Lewy body pathology
Spastic paraparesis PSEN1 DelIM
PSEN1 Δexon9
PSEN1 Y154N
PSEN1 F237I
PSEN1 V261F
PSEN1 P264L
PSEN1 G266S
PSEN1 R278K
PSEN1 R278T
PSEN1 E280G
PSEN1 P284L
PSEN1 P436Q
Cotton wool plaques
Cotton wool plaques
Cotton wool plaques
Cotton wool plaques
Cotton wool plaques
Cotton wool plaques
Extrapyramidal signs PSEN1 S170F
PSEN1 G217D
PSEN1 M223V
PSEN1 DelT440
PSEN2 A85V
Lewy body pathology
Cotton wool plaques & amyloid angiopathy
Lewy body pathology
Cotton wool plaques & Lewy body pathology
Lewy body pathology
Cerebellar signs PSEN1 P117A
PSEN1 S170F Severe Purkinje cell somata and dendritic loss
Focal neurological
symptoms & signs
‘Dutch’ APP E693Q
‘Flemish’ APP A692G
Amyloid angiopathy with recurrent cerebral
haemorrhagesInfluence of mutation location on pathology and phenotype
Presenilin 1 mutations
Two distinct histopathological profiles have been identified in FAD caused by PSEN1
mutations and the type of pathology appears to be driven by the position of the
mutation within the gene.
(11) Mutations occurring before codon 200 are more
frequently associated with a type1 pattern of pathology whilst mutations beyond
codon 200 tend to have type 2 pathology, which includes more severe amyloid
angiopathy. Type 1 pathology more closely resembles the pathology seen in sporadic
AD, with many diffuse and cored plaques and few white matter plaques. Amyloid
angiopathy is only mild to moderate, and is usually confined to leptomeningeal
vessels. In type 2 pathology, the number and distribution of diffuse and cored plaques
is similar but these tend to be much larger and concentrated around amyloidotic
arteries. Amyloid angiopathy is nearly always severe, involving both leptomeningeal
and intraparenchymal arteries. Aβ40 deposition tends to be increased in those with
type 2 pathology, and this effect is independent of APOE genotype. The distinction
between the two types of pathology is not absolute; some mutations occurring before
codon 200 have been associated with widespread amyloid angiopathy, such as
E184D
(62) and DelI83/M84.
(63) Equally, the N405S mutation, occurring after codon
200, appears to produce limited amyloid angiopathy.
(64) However, there do appear to
be clinical implications of the different histopathological signatures. Individuals with
type 1 pathology have a younger age at onset (by on average 5 years) and shorter
disease duration (by around 2.5 years) than those with type 2 pathology.
In order to explain the dichotomous manner by which the mutation site influences the
development of amyloid angiopathy, it has been suggested that PSEN1 mutations may
actually act through two separate pathways.
(11) First, they increase the production and
deposition of Aβ42 and secondly, by affecting Notch signalling, they induce
breakdown of the vascular epithelium. The subsequent leakage of Aβ into brain tissue
may seed onto existing deposits of Aβ, producing the large plaques seen around
vessels in type 2 pathology, and promoting the development of amyloid angiopathy.
Interestingly, the residues of PSEN1 that are thought to be functionally most
important, namely aspartyl residues at the active site and PSEN1 cleavage site, arelocated in the region of the gene where mutations are associated with severe amyloid
angiopathy. Also important is the observation that these type 2 cases have less
aggressive phenotypes, with later ages at onset and longer disease durations.
APP mutations
The majority of APP mutations reported to date lie in the vicinity of the β and γ 
secretase cleavage sites. APP residue 717, located just distal to the C-terminus of the
Aβ domain by the γ secretase site, was recognised early on to represent a mutation
hotspot. The ‘London’ APP V717I mutation was the first described, comprising
valine substituted by isoleucine, but valine substituted by glycine, phenylananine or
leucine at the 717 codon also results in a similar phenotype. Families with mutations
at this site were found to share common features of early impairment of episodic
memory, dyscalculia, lack of insight and prominent myoclonus and seizures.
(65) A
double point mutation at APP 670/671 (G to T, A to C), resulting in a lysine
methionine to asparagine leucine double substitution, was later identified in two
Swedish families.
(66) This double mutation frames the other end of the Aβ domain,
lying at the N-terminus by the β secretase site.
Some mutations have also been found within the Aβ coding sequence, and these
appear to have specific pathological and clinical features, particularly in relation to
amyloid angiopathy (Table 2). The ‘Dutch mutation’ in APP; a missense mutation
resulting in a glutamate to glutamine substitution at position 693 (APP E693Q) gives
rise to a highly distinct phenotype.
(67) These individuals have severe amyloid
angiopathy leading to recurrent cerebral haemorrhage. The main clinical features are
focal neurological symptoms and signs relating to these cerebrovascular events,
although most patients do also develop dementia. Pathologically, diffuse parenchymal
deposits of Aβ are observed, but the hallmark neuritic plaques and neurofibrillary
tangles of AD are absent. A neighbouring mutation at residue 692 (an alanine to
glycine substitution) has been reported in a separate family and labelled the Flemish
mutation.
(68) The affected individuals suffered either haemorrhages or a progressive
dementia or both. A biopsy of a family member with haemorrhages revealed amyloid
angiopathy with sparse neuritic plaques but no neurofibrillary tangles.Presymptomatic carriers of the Flemish mutation have also been investigated and
found to have significantly increased periventricular and subcortical white matter
lesions on cranial MRI.
(69)
Another APP mutation within the Aβ sequence, known as the Iowa mutation (APP
D694N) has also been found to be associated with severe amyloid angiopathy on
pathological investigation. Widespread neurofibrillary tangles and amyloid plaques
with particularly abundant Aβ40 deposition are seen with this mutation. Clinically,
however, these affected individuals lacked symptoms of recurrent cerebrovascular
events and presented with progressive cognitive impairment.
(70) A similar picture was
found with the recently identified ‘Arctic’ mutation APP E693G, which has a purely
cognitive phenotype, typical of AD, despite the presence of marked amyloid
angiopathy.
(71) The pathological findings in the Arctic mutation also include
neurofibrillary tangles and abundant amyloid plaques with characteristic ring-like
structures. Why the presence of amyloid angiopathy should have clinical
manifestations with some of these mutations but not with others is intriguing. This is
particularly true for the Arctic and Dutch mutations, which occur at exactly the same
position (amino acid 693) but give rise to totally different phenotypes. It has been
proposed that the explanation may lie in polarity of the substituted amino acid. The
Dutch mutation involves replacement of a glutamic acid with glutamine, which is
polar and hydrophilic. Dutch Aβ may therefore have a greater affinity for, and
propensity to disrupt, the vessel wall than Arctic Aβ, which is non-polar and
hydrophobic.
(71)Table 2: Clinical and pathological features of APP mutations lying
within the Aβ coding domain
APP
Mutation
Cerebral
amyloid
angiopathy
Amyloid
plaques
Neurofibrillary
tangles
Clinical Phenotype
Flemish
A692G
Present Present Absent Recurrent cerebral
haemorrhage or dementia or
both
Dutch
E693Q
Present Absent Absent Predominantly recurrent
cerebral haemorrhage.
Usually also followed by
dementia
Arctic
E693G
Present Present, with
characteristic
ring-like
structure
Present Dementia only
Iowa
D694N
Present Present, with
extensive
Aβ40
deposition
Present Dementia only
APP duplications
The well established link between Down’s syndrome and AD provided early evidence
that copy number variation may play a role in AD pathogenesis and it is now known
that duplications of the APP gene can give rise to FAD.
(4) The phenotype associated
with APP duplication can be diverse, even within a single family.
(72) However,
characteristic features include a high frequency of seizures, up to 57% in one series,
and prominent amyloid angiopathy.
(4) The size of the duplication does not appear to
influence the clinical presentation. The cognitive phenotype resembles that of typical
AD, with early progressive impairment of episodic memory. In some families, the
clinical presentation is solely cognitive, with no distinguishing neurologicalfeatures.
(73) Knowledge of the prevalence of APP duplications and spectrum of
associated clinical features is likely to expand as increasing numbers of centres search
for copy number variation in their cohorts of patients.
Interestingly, a recent post-mortem study of an individual with an APP duplication
revealed diffuse neocortical Lewy body pathology (LBP) with additional amyloid
angiopathy and AD pathology.
(72) The clinical phenotype of this patient, comprising
cognitive decline associated with visual hallucinations and extrapyramidal signs, was
also compatible with a diagnosis of dementia with Lewy bodies. As the authors
suggest, this case adds weight to the hypothesis that accumulation of Aβ can induce
LBP. However, further work must be done in larger cohorts of patients to elucidate
more about the clinical manifestations of coexistent Lewy body pathology in FAD,
and to investigate the relationship between β-amyloid and alpha-synuclein in
neurodegenerative disease in general.
Genetic factors in sporadic AD
In FAD, genetic factors clearly modify the clinical phenotype in striking ways. The
manifestations of sporadic AD are also likely to be influenced by genetic factors,
though generally in a far subtler manner. The involvement of the APOE gene in
sporadic AD has long been known, with possession of the E4 allele conferring both an
increased risk of developing the disease and possibly driving the pathology towards
limbic areas.
(74) Genome-wide association studies have recently revealed three new
‘risk genes’ for sporadic AD: CLU, PICALM and CR1.
(75),
(76) An important direction
for future work will be to investigate whether these variants have phenotypic
associations, particularly in sporadic AD but also in familial disease.
Genes known to cause FAD may also play a role in sporadic disease. There are certain
PSEN1 polymorphisms, for example E318G, whose pathogenic nature remains
uncertain. It has been suggested that some PSEN1 polymorphisms may modify the
phenotype of sporadic AD by altering the rate of cognitive decline.
(77)There is recent evidence demonstrating that FAD-causing gene mutations may
sometimes be even more directly implicated in cases of apparently sporadic AD;
through somatic and germline mosaicism.
(78) An individual who underwent negative
genetic testing on a peripheral blood sample was subsequently found to have the
PSEN1 P436Q mutation in DNA extracted from cerebral cortex. Although this
proband had no family history of dementia herself, one of her daughters subsequently
developed symptoms and was found to have inherited the mutant haplotype from her
mother. Interestingly, the two affected individuals had a difference in age at onset of
around 15 years and strikingly different clinical phenotypes, although both featured
prominent neurological signs. As the authors suggest, these findings have several
important implications. Differing levels of mosaicism may account for some of the
phenotypic variation seen in FAD. Furthermore, there may be many patients with AD
who have pathogenic somatic mutations expressed in brain tissue that are not found
on conventional sequencing of DNA extracted from blood lymphocytes.
Conclusion
In the past two decades, significant advances have been made in our understanding of
FAD at a molecular, genetic, pathological and clinical level. The number of known
mutations has risen exponentially and, with them, an expanding spectrum of clinical
phenotypes has been identified. Observations of how certain symptoms and signs tend
to cluster with particular mutations has led to an appreciation of how the location of a
mutation within a gene can dictate the type of pathology that develops, particularly in
relation to amyloid angiopathy. Familial and sporadic AD have been shown to share
many similarities. They commonly present with identical symptoms of impaired
episodic memory but can both, more rarely, have initial deficits in other cognitive
domains. The factors dictating the topography of pathology in both familial and
sporadic disease remain to be elucidated. However, possible mechanisms have been
proposed. As has always been the case, the insights gained from studying FAD
continue to inform our understanding of AD in general. With the prospect of disease-
modifying therapy focussing interest on detecting the earliest stages of disease,
longitudinal study of the presymptomatic phase in individuals destined to develop
FAD will be more important than ever.Future perspective
There is a growing appreciation of how knowledge gleaned from the study of familial
Alzheimer’s disease has the potential to increase our understanding of Alzheimer’s
disease as a whole. In recognition of this, the first international collaborative study of
individuals carrying FAD mutations has recently been launched; the dominantly
inherited Alzheimer network (DIAN). This multicentre study will collect longitudinal
data to explore the clinical, imaging, neuropsychological, blood and cerebrospinal
fluid changes that occur in the long period leading up to symptom onset in FAD. By
establishing the largest cohort of FAD patients studied to date, it will allow some of
the unresolved questions surrounding the relationship between genotype and
phenotype in FAD to be addressed. Aided by initiatives like DIAN, research into
FAD is likely to progress at an accelerating pace over the coming decade. The advent
of disease-modifying therapy provides great momentum for driving forward this
progress, as it creates an unprecedented need to understand the pathogenesis of AD in
more detail. Issues such as the relationship between AD pathology and amyloid
angiopathy, for example, have been brought to the forefront by recent immunotherapy
trials. It has been found that, in patients treated with Aβ42 immunotherapy, removal
of amyloid plaques may be accompanied by accumulation of Aβ42 in perivascular
drainage pathways, with an associated transient increase in amyloid angiopathy.
(79) It
appears that this plaque-derived Aβ42 can be cleared, given sufficient time.
(80)
However, factors including APOE genotype are likely to influence how effectively
this is achieved. Understanding more about the mechanisms underlying the variable
occurrence and clinical manifestation of amyloid angiopathy in FAD may thus have
far-reaching implications. It is clear that in both familial and sporadic AD, a range of
atypical clinical phenotypes can occur and by understanding more about how genetic
factors modify the pathological and clinical picture, we may find that the phenotype
contains clues suggesting the most appropriate treatment for an individual.Executive summary
Autosomal dominantly inherited genetic changes can cause early onset AD
 Mutations in the amyloid precursor protein (APP), presenilin 1 (PSEN1) and
presenilin 2 (PSEN2) genes, together with APP duplications, may give rise to
familial Alzheimer’s disease (FAD).
 Fewer mutations have been identified in PSEN2 or APP than PSEN1, which
accounts for the majority of cases of FAD.
 FAD accounts for only up to 0.5% of all Alzheimer’s disease.
 Study of FAD gene mutations has informed much of our current knowledge of
AD pathogenesis and has facilitated the development of putative treatments.
Role of genetic mutations in AD pathogenesis
 All of the genetic changes known to cause FAD ultimately result in enhanced
production and/or deposition of β-amyloid.
 Consequently, individuals with FAD generally have much earlier ages at onset
of disease than those with sporadic AD.
 The youngest ages at onset are seen with mutations in PSEN1, which may also
be associated with shorter disease durations. Older ages at onset occur with
APP mutations and the oldest with PSEN2.
 Other genetic and epigenetic factors may contribute to the range in age at
onset and variable phenotype that is witnessed both between and within
families with the same mutation.
 The APOE4 allele is associated with younger age at onset in sporadic AD and
FAD secondary to APP mutations, though the relationship in PSEN1-
associated FAD is less clear.
Cognitive phenotype of familial and sporadic AD
 FAD typically presents with insidious impairment of episodic memory, which
may be comparable to the amnestic MCI prodrome of sporadic AD.
 Presymptomatic changes of impaired verbal memory and performance IQ, and
accelerating brain atrophy on MRI, have been detected in FAD. Atypical presentations, involving other cognitive domains prior to memory,
occur in familial and sporadic AD. Language and behavioural variants are
seen in both but the visual variant of posterior cortical atrophy has only been
reported to occur in sporadic disease.
Neurological symptoms and signs in FAD
 Neurological symptoms and signs occur more frequently in familial than
sporadic AD, particularly in very early onset cases, before the age of 40y.
 Myoclonus and seizures can occur early in the disease course and may precede
cognitive symptoms.
 PSEN1 mutations may be associated with spastic paraparesis, extrapyramidal
signs or cerebellar ataxia and these may rarely be the presenting features.
 Spastic paraparesis is often associated with PSEN1 exon 9 deletions.
Characteristic histopathological features called cotton wool plaques are
frequently seen in these cases. These have also been found in PSEN1-
associated FAD presenting with Parkinsonism.
 Severe cerebellar Aβ deposition has been observed in some PSEN1 and
APP717 mutations.
Influence of mutation location on pathology and phenotype
 PSEN1 mutations before codon 200 have similar histopathology to sporadic
AD whilst those beyond it produce more severe amyloid angiopathy, though a
later and longer disease course.
 The ‘Dutch’ and ‘Flemish’ APP mutations located within the Aβ coding
sequence cause severe amyloid angiopathy with recurrent haemorrhage and
focal neurological symptoms and signs. Neighbouring ‘Iowa’ and ‘Arctic’
APP mutations also show amyloid angiopathy, although the phenotype is
purely cognitive.
 Duplications of the APP gene can cause FAD, often with prominent amyloid
angiopathy and a high seizure frequency.
 Concomitant Lewy body pathology occurs in up to 60% of familial and
sporadic AD and may also be seen with APP duplications, suggesting it maybe induced by Aβ deposition. There may be clinical correlations of visual
hallucinations and Parkinsonism.
Genetic factors in sporadic AD
 The APOE4 genotype is a well established risk factor for sporadic AD but
three additional risk genes, CLU, PICALM and CR1 have also recently been
identified.
 Genes known to cause FAD may also play a role in sporadic disease; it has
been suggested that PSEN1 polymorphisms may affect the rate of cognitive
decline.
 Cases of apparently sporadic AD may sometimes be caused by PSEN1
mutations through somatic and germline mosaicism. Differing levels of
mosaicism may also contribute to phenotypic heterogeneity.
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Recommended references
4. Duplication of the APP locus found to be a cause of autosomal dominantly
inherited early onset AD, with prominent amyloid angiopathy.
5 & 6. Comprehensive review of the various different atypical features reported in
association with PSEN1 mutations with more recently published update.
11. The histopathological profile in PSEN1 mutations appears to be driven by the
position of the mutation in the gene, with more severe amyloid angiopathy
observed in mutations beyond codon 200.14. Neuropsychological deficits, manifested in a fall in performance IQ and verbal
memory scores, are detectable several years prior to symptoms onset in FAD
mutation carriers.
16. Global brain atrophy increases with advancing disease in FAD, and regional
hippocampal atrophy is already occurring prior to the onset of symptoms.
33. Detailed review of the association between Alzheimer’s disease and spastic
paraparesis.
78. This paper introduces somatic and germline mosaicism as novel disease
mechanisms in AD, reporting an individual demonstrating a PSEN1 mutation in
DNA extracted from cerebral cortex, which was not detectable on peripheral
blood sequencing.